Uncategorized
Valeant announces $2 billion Securities Repurchase Program
A new securities repurchase program that will allow Valeant Pharmaceuticals to make purchases up to $2 billion of its senior notes, common shares and other securities will replace the company’s expiring program, according to a company press release. The board of directors also authorized a sub-limit for the repurchase of Valeant common shares of more than 10% of the company’s public float and 5% of the company’s issued and outstanding common shares, according to the press release.